Balchem Corp. 10-K Summary: Fiscal Year Ended December 31, 1998
Business Context and Reporting Period
Balchem Corporation (BALCHEM) is a specialty performance ingredient developer and manufacturer serving the food, feed, and medical sterilization industries. The company operates two primary segments: Encapsulated Products (micro-encapsulation for food/feed) and Specialty Products (packaging and marketing of specialty gases like ethylene oxide). This report covers the fiscal year ended December 31, 1998.
Key Financial Metrics
| Metric (in thousands, except per share) | 1998 | 1997 |
|---|---|---|
| Net Sales | $28,721 | $28,619 |
| Gross Margin | $11,423 (39.8%) | $11,914 (41.6%) |
| Net Earnings | $2,955 | $2,771 |
| Diluted EPS | $0.60 | $0.57 |
| Operating Cash Flow | $3,893 | $2,994 |
| Total Assets | $22,648 | $17,593 |
| Long-Term Debt | $3,750 | $1,500 |
| Stockholders' Equity | $15,775 | $12,336 |
Material Changes vs. Prior Period
- Revenue Stability: Net sales increased marginally by $102 (0.4%) to $28.7 million. The Specialty Products segment declined 1% due to a customer switching to bulk purchasing, while the Encapsulated Products segment grew 4% driven by domestic/international food and animal nutrition volumes.
- Profitability: Net earnings rose 7% to $2.955 million. Operating expenses decreased 13% year-over-year, largely due to the reversal of a $187k bad debt reserve established in 1997 and the absence of $302k in 1997 reorganization charges.
- Debt Increase: Long-term debt increased significantly from $1.5 million to $3.75 million. This was driven by a $3.0 million borrowing to fund a $3.7 million final payment on a contingent purchase price obligation for the 1994 acquisition of the ethylene oxide business.
- Segment Performance: Pre-tax profit for Specialty Products increased to $4.631 million, while Encapsulated Products profit improved to $176k from $116k.
Outlook, Risks, and Management Commentary
- Regulatory Contingency: The company's ability to sell ethylene oxide depends on EPA re-registration, expected to be completed in 2000. Management believes re-registration is likely but notes the product has no known substitute, making it critical to the medical device industry.
- Customer Concentration: One customer, Griffith Microsciences, Inc., accounted for 14.8% of 1998 net sales. Loss of this customer could have a material adverse effect.
- Year 2000 Compliance: The company is implementing Y2K compliant software, with completion anticipated by mid-1999. Estimated total project costs range from $75k to $140k, with $60k incurred in 1998.
- Capital Expenditures: 1998 capex was $1.637 million for plant expansion. 1999 capex is projected at approximately $700k.
- Dividends: A dividend of $0.033 per share was declared in 1998. Dividend payments are restricted by the company's lending agreement.
Investor Verification Checklist
- EPA Re-registration Status: Verify the timeline and certainty of the ethylene oxide re-registration process with the EPA, as this is a critical operational dependency.
- Customer Concentration Risk: Assess the stability of the relationship with Griffith Microsciences, Inc., which represents nearly 15% of revenue.
- Debt Service Capacity: Review the impact of the increased debt load ($3.75M) on future liquidity and interest coverage ratios, particularly given the LIBOR + 1% interest rate structure.
- Y2K Implementation: Confirm the completion of internal Y2K remediation and the status of contingency plans for third-party suppliers.
- Raw Material Volatility: Monitor the company's ability to pass on raw material cost increases to customers, as noted in the risk factors.